// App-Quantinova.ai

333 : Carfilzomib Combined with Thalidomide and Dexamethasone (CTD) Is an Highly Effective Induction and Consolidation Treatment in Newly Diagnosed Patients with Multiple Myeloma (MM) Who Are Transplant Candidate

Researchers

Presenter

  • Emilie Asselbergs

Principal Investigators

  • Sonja Zweegman

  • Bronno van der Holt

  • Marie Jose Kersten

  • Edo Vellenga

  • Marinus van Marwijk-Kooy

  • Okke de Weerdt

  • Sarah Lonergan

  • Henk Lokhorst

Medical Centers

  • Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands

  • Hematology, Erasmus Medical Center, Rotterdam, Netherlands

  • Department of Pathology, University Medical Center Utrecht, Utrecht, Netherlands

  • Hematologie VUMC, Amsterdam, Netherlands

  • HOVON Data Center Easmus Medical Center, Rotterdam, Netherlands

  • Hematology, Isala Clinics, Zwolle, Netherlands

  • Hematology, Erasmus Medical Center, Rotterdam, Netherlands

  • Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands

  • Erasmus University Medical Center, Rotterdam, Netherlands

  • Department of Internal Medicine, St. Antonius Hospital, Nieuwegein, Netherlands

Locations

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Tumor lysis syndrome

  • Multiple Myeloma

  • Peripheral neuropathy

Biomarkers

  • Circulating tumor cells

  • Cluster of Differentiation 34

  • Granulocyte colony-stimulating factor

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • carfilzomib Intravenous

  • Thalidomide

  • Melphalan

  • Filgrastim

Outcome

  • N/A

Study Design

  • double blind/blinded

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved